Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Seminars in Oncology 1985-Sep

Biological heterogeneity of small cell lung cancer.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
D N Carney
A F Gazdar
M Nau
J D Minna

Maneno muhimu

Kikemikali

Over the past 20 years considerable advances have been made in the characterization of the biologic properties of small cell lung cancer. The recognition that this histologic type of lung cancer, in contrast to the other major types of lung cancer, is highly sensitive to both chemotherapy and radiation therapy lead to significant improvements in the overall survival of patients with this disease. However, in spite of the initial major advances in therapy, overall results and survival have remained unchanged over the past 5 years. The majority of patients, although they will demonstrate an initial response to cytotoxic therapy, will ultimately die of their disease due to the development of drug resistance. Whether this development of drug resistance within a tumor cell represents the emergence of resistant clones of cells present at diagnosis, or a change within the cells exposed to cytotoxic therapy that renders them resistant to further therapy remains to be determined. The development of laboratory techniques that facilitate the culture and establishment of SCLC cell lines has greatly improved our understanding of the biology of SCLC, in addition to providing useful models for studies of mechanisms of drug resistance and metabolism. The ease of establishment of SCLC cell lines in defined medium suggests that these cells secrete "autocrine growth factors" essential for their growth in vitro. The characterization of these factors may provide an alternative means for treating this tumor in vivo. Moreover, by developing specific culture media for other types of lung cancer, similar advances in our knowledge of these tumors will occur. Although the growth of SCLC cells in a clonogenic assay may be of value in chemotherapy selection, the established cell lines provide a model for studying mechanisms of drug and radiation sensitivity; and drug metabolism. The recognition that SCLC cell lines have elevated levels of L-dopa decarboxylase has lead to the development of specific agents that may alter the growth of these cells through inhibition of polyamine synthesis. Such specifically designed therapy may become important in the future therapy of these patients. The establishment of cell lines has clearly indicated the considerable heterogeneity that exists in SCLC.(ABSTRACT TRUNCATED AT 400 WORDS)

Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge